The notices it replaced
- Reissues: PAR-20-092 Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)
- 2 steps back: RFA-DA-19-002 Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trials Optional)
Replaced by PAR-25-329.
Who won it before
74 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $231,898,594 in first-year total cost, median $2,920,292.
Most frequent study sections
- Special Emphasis Panel[ZDA1 IXN-O (01)]24
- Medication Development Research Study Section[NIDA-L]23
- Special Emphasis Panel[ZDA1 IXN-O (11)]9
- Special Emphasis Panel[ZDA1 IXN-O (17)]6
- Special Emphasis Panel[ZDA1 IXN-O (04)]3
Most frequent institutions
- VIRGINIA COMMONWEALTH UNIVERSITY4
- NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC3
- SPARIAN BIOSCIENCES, INC.3
- ENSYSCE BIOSCIENCES, INC.2
- ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI2
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | MEB-1170: A New Chemical Entity for the Treatment of Opioid Use Disorder1UG3DA063357-01 | COMER, SANDRA D.FREEMAN, KEVIN B.KUO, LAWRENCE CREINES, SCOTT A. | MEBIAS DISCOVERY, INC., CT | $4,710,576 | ZDA1 |
| 2025 | IND-enabling studies and phase I clinical trials to advance CD74-target, DRhQ, as a treatment for stimulant use disorder1UG3DA061709-01 | LOFTIS, JENNIFER MMURNANE, KEVIN SEANSHIRLEY, RENEE LYNN | VIROGENOMICS BIODEVELOPMENT, INC., OR | $3,287,052 | NIDA |
| 2025 | Clinical Development of SBS-147: First-in-class Oral Arylepoxamide Agonist for Pain1UG3DA064392-01 | ASHWORTH, JUDYPASTERNAK, ANNA | SPARIAN BIOSCIENCES, INC., NY | $3,138,031 | NIDA |
| 2025 | Development of a bioabsorbable, subcutaneous, extended-release buprenorphine implant for opioid use disorder1UG3DA062511-01 | BENNER, JEFFREYCOHEN, STEVEN M | AKYSO THERAPEUTICS, LLC, MD | $2,932,500 | NIDA |
| 2025 | Optimization and Development of Non-Hallucinogenic 5-HT2A/2C Agonists as Opioid Use Disorder Therapeutics1UG3DA064403-01 | SHORT III, GLENN | ATAI THERAPEUTICS, INC., NY | $2,923,842 | NIDA |
| 2025 | Development of negative allosteric modulators at the mu opioid receptor1UG3DA063363-01 | KOBILKA, BRIAN KMAJUMDAR, SUSRUTAMCLAUGHLIN, JAY P.SUN, BINGFA | WASHINGTON UNIVERSITY, MO | $2,664,000 | NIDA |
| 2025 | Repurposing FDA-approved oxytocin to treat opioid-induced respiratory depression1UG3DA062506-01A1 | MENDELOWITZ, DAVIDPOLOTSKY, VSEVOLOD Y | GEORGE WASHINGTON UNIVERSITY, DC | $2,104,389 | NIDA |
| 2025 | Advancing a non-addictive, peripherally acting opioid analgesic as a medication strategy to prevent opioid use disorder in patients undergoing treatment for pain1UG3DA061645-01A1 | SANDERS, VIRGINIA J | DIMERX, CA | $1,593,126 | NIDA |
| 2025 | Novel 5-HT2A/mGluR5 Antagonist for Opioid Use Disorder1UG3DA063353-01 | MARTIN, CAITLIN EILEENMOELLER, FREDERICK GERARD | VIRGINIA COMMONWEALTH UNIVERSITY, VA | $1,153,945 | NIDA |
| 2025 | Glutide for Ending Methamphetamine1UG3DA063329-01 | COFFIN, PHILLIP O | PUBLIC HEALTH FOUNDATION ENTERPRISES, CA | $977,129 | NIDA |
| 2024 | Development of SBS-226, a MOR agonist / DOR antagonist, for OUD1UG3DA059278-01A1 | REICH, JEFFREY | SPARIAN BIOSCIENCES, INC., NY | $3,957,359 | NIDA |
| 2024 | Registration Development Program for LUCEMYRA (Lofexidine) Label Expansion for Opioid Withdrawal Treatment in Adolescents1UG3DA061620-01 | MASSEY, VERONICA LYNCHSCHMIDT, LEE | USWM, LLC, KY | $2,916,742 | NIDA |
| 2024 | Development of a Safer and More Effective Ibogaine Analog for the Treatment of Opioid Use Disorder1UG3DA060053-01 | MAREK, GERARD JOSEPH | GILGAMESH PHARMACEUTICALS INC, NY | $2,747,151 | NIDA |
| 2023 | Development of a Potent and Selective Nav1.8 inhibitor for the Treatment of Acute and Chronic Pain with the Goal of Reducing Opioid Use and Preventing Opioid Use Disorders1UG3DA058552-01 · under PAR-20-092 | HUNTER, JOHN CURETONMULCAHY, JOHN VINCENT | SITEONE THERAPEUTICS, INC., CA | $5,341,667 | NIDA |
| 2023 | Antibody-based therapy for fentanyl-related opioid use disorder1UG3DA058544-01A1 | BREMER, PAUL TDESAI, RAJEEV INDRAJIT | MCLEAN HOSPITAL, MA | $4,202,550 | NIDA |
| 2023 | Development of cebranopadol, a potent dual MOP/NOP agonist, for the treatment of Opioid Use Disorder (OUD)1UG3DA059285-01 | CICCOCIOPPO, ROBERTOGREENWALD, MARK KGRIECO, JOSEPH | PARK THERAPEUTICS, INC., NJ | $3,329,591 | NIDA |
| 2023 | A Therapeutic Agent to Lower the Level of Synthetic Opioids in the Body1UG3DA059286-01 | LI, XINHUA | CLEAR SCIENTIFIC, LLC, MA | $3,035,865 | NIDA |
| 2023 | Development of sigma receptor/DAT dual-targeting compounds to treat stimulant use disorder1UG3DA058553-01 · under PAR-20-092 | REICH, JEFFREY | SPARIAN BIOSCIENCES, INC., NY | $2,886,286 | NIDA |
| 2023 | Long acting biodegradable buprenorphine depots1UG3DA059270-01 | OTTE, ANDREW | PURDUE UNIVERSITY, IN | $631,404 | NIDA |
| 2022 | Development of a monoclonal antibody to reverse overdose from fentanyl and its analogs: from manufacturing to clinical trials1UG3DA057850-01 · under PAR-20-092 | COMER, SANDRA DPRAVETONI, MARCO | UNIVERSITY OF WASHINGTON, WA | $8,267,350 | ZDA1 |
| 2022 | Phase 1 and 2 studies of sublingual dexmedetomidine, an alpha 2 adrenergic agonist, for treating opioid withdrawal1UG3DA056247-01 · under PAR-20-092 | COMER, SANDRA DLEVIN, FRANCES RUDNICK | NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC, NY | $3,312,204 | ZDA1 |
| 2022 | Naltrexone Transdermal Patch - An Accessible, Patient-Focused Option to Treat OUD Relapse1UG3DA057853-01 · under PAR-20-092 | GARDINER, ANDREW | LIBERO PHARMA LIMITED | $3,187,507 | NIDA |
| 2022 | Development of Specific Mu Opioid Receptor Antagonists to Reverse the Acute and Chronic Toxicity of Fentanyls1UG3DA054785-01A1 · under PAR-20-092 | ZHANG, YAN | VIRGINIA COMMONWEALTH UNIVERSITY, VA | $2,824,374 | NIDA |
| 2021 | An Intranasal GDNF Gene Therapy for Opioid Relapse Reduction1UG3DA050942-01A1 · under PAR-20-092 | BYRNES, ELIZABETH MPOTHOS, EMMANUEL NWASZCZAK, BARBARA LEE | NORTHEASTERN UNIVERSITY, MA | $6,693,512 | ZDA1 |
| 2021 | CVL-354, a kappa opioid receptor antagonist for treatment of opioid use disorder, withdrawal and relapse1UG3DA052166-01A1 · under PAR-20-092 | IREDALE, PHILIPLEONI, MATTHEW | CEREVEL THERAPEUTICS, LLC, MA | $5,400,000 | NIDA |
| 2021 | Development of Lofexidine as a First-line Non-Opioid Pharmacologic Treatment for Neonatal Opioid Withdrawal Syndrome1UG3DA054799-01 · under PAR-20-092 | GULLO, KRISTEN LEANNSEBURG, RANDAL | USWM, LLC, KY | $5,353,314 | NIDA |
| 2021 | A novel and highly selective orexin 1 receptor antagonist for the treatment of patients with opioid use disorder.1UG3DA054825-01 · under PAR-20-092 | OSTENFELD, THORTHOMSON, FIONA J. | ASTRAZENECA PHARMACEUTICALS, LP, DE | $3,032,676 | NIDA |
| 2021 | Bacteriophage virus-like particle vaccines for fentanyl and heroin overdose1UG3DA053123-01 · under PAR-20-092 | CHACKERIAN, BRYCE C | UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR, NM | $1,572,708 | ZDA1 |
| 2020 | Evaluation of the Safety and Efficacy of a New Oral Small Molecule GABA-B Receptor Positive Allosteric Modulator (PAM) as an Add-on Maintenance Therapy for Opioid Use Disorder (OUD)1UG3DA051392-01 · under RFA-DA-19-002 | ERDMAN, JAYMAREK, GERARD JOSEPH | ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC., IL | $6,000,000 | ZDA1 |
| 2020 | Brexpiprazole as an adjunctive treatment to buprenorphine to treat Opioid Use Disorder1UG3DA051383-01A1 · under PAR-20-092 | FORBES, ANDY | OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC., NJ | $4,023,155 | ZDA1 |
| 2020 | NOP Receptor Antagonist for OUD Pharmacotherapy1UG3DA052282-01 · under RFA-DA-19-002 | CUNNINGHAM, KATHRYN A.MOELLER, FREDERICK GERARD | UNIVERSITY OF TEXAS MED BR GALVESTON, TX | $2,793,808 | ZDA1 |
| 2020 | AMPA Antagonism: A Novel Pharmacology for Launching Recovery from Opioid Addiction1UG3DA050923-01 · under RFA-DA-19-002 | CHAMBERS, ROBERT ANDREWTOOMBS, CHRISTOPHER FRANCIS | INDIANA UNIVERSITY INDIANAPOLIS, IN | $1,854,492 | ZDA1 |
| 2019 | Cannabidiol in the treatment of opioid use disorder1UG3DA050323-01 · under RFA-DA-19-002 | HURD, YASMIN L. | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $7,484,180 | ZDA1 |
| 2019 | A once-weekly oral methadone for maintenance therapy for opioid use disorder1UG3DA050310-01 · under RFA-DA-19-002 | SCRANTON, RICHARDZALE, STEPHEN | LYNDRA THERAPEUTICS, INC., MA | $6,854,394 | ZDA1 |
| 2019 | Novel Therapeutics for Opioid Use Disorder in the Acute Overdose and Maintenance Settings1UG3DA049598-01 · under RFA-DA-19-002 | GEHLERT, DONALD RSCHMIDT, WILLIAM K | EPIODYNE, INC., CA | $6,461,202 | ZDA1 |
| 2019 | Nalmefene Long-Acting Injectable (AP007) for the Treatment of Opioid Use Disorder1UG3DA048745-01A1 · under RFA-DA-19-002 | WALKER, ANDREW | EMERGENT PRODUCT DEVELOPMENT GAITHERSBUR, MD | $6,354,906 | ZDA1 |
| 2019 | R-methadone-TAAP/MPAR: an abuse deterrent methadone prodrug with overdose protection: Pre-Clinical Development and Phase 1 Clinical Trial1UG3DA050271-01 · under RFA-DA-19-002 | KIRKPATRICK, LYNN | ENSYSCE BIOSCIENCES, INC., CA | $5,389,398 | ZDA1 |
| 2019 | Combining Pregabalin with Lofexidine: Can it Increase the Success of Transition to Naltrexone?1UG3DA049694-01 · under RFA-DA-19-002 | KAMPMAN, KYLE MATTHEWWOODY, GEORGE EDWARD | UNIVERSITY OF PENNSYLVANIA, PA | $4,061,892 | ZDA1 |
| 2019 | Development of SBI-553, an allosteric modulator of NTR1, for the treatment of substance use disorders1UG3DA050316-01 · under RFA-DA-19-002 | BARAK, LAWRENCE S.CARON, MARC G.GUPTILL, JEFFREY TJACKSON, MICHAEL | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $3,588,880 | ZDA1 |
| 2019 | Arylepoxamides: A new class of potent, safer analgesics1UG3DA048379-01 · under RFA-DA-19-002 | PAN, YING-XIAN | SLOAN-KETTERING INST CAN RESEARCH, NY | $3,263,463 | ZDA1 |
| 2019 | Development of ITI-333, a μ-opioid Receptor Partial Agonist and 5HT2A and D1 Receptor Antagonist, for the Treatment of Opioid Use Disorders1UG3DA047699-01 · under RFA-DA-19-002 | COMER, SANDRA DSNYDER, GRETCHEN LWONG, DEAN FOSTER | INTRA-CELLULAR THERAPIES, INC., NY | $3,249,130 | ZDA1 |
| 2019 | Development of a safe and effective novel mechanism analgesic to treat moderate to severe pain with low or absent abuse liability.1UG3DA047708-01 · under RFA-DA-19-002 | LARK, MICHAEL WILLIAMZADINA, JAMES E | ARTYS BIOTECH, LLC, PA | $3,102,560 | ZDA1 |
| 2019 | A Long-Acting Bioabsorbable Naltrexone Subcutaneous Implant for Opioid Use Disorder1UG3DA048338-01A1 · under RFA-DA-19-002 | BENNER, JEFFREYCOHEN, STEVEN M | DRUG DELIVERY COMPANY, LLC, THE, MD | $3,083,969 | ZDA1 |
| 2019 | Development of a novel drug for treating opioid use disorder1UG3DA048234-01 · under RFA-DA-19-002 | SHAH, NIKEJVOCCI, FRANK J. | NIRSUM LABORATORIES, INC., NY | $3,060,540 | ZDA1 |
| 2019 | Development of a Soluble Epoxide Hydrolase Inhibitor to Spare or Replace Opioid Analgesics1UG3DA048767-01 · under RFA-DA-19-002 | BUCKPITT, ALAN RHAMMOCK, BRUCE D | EICOSIS, LLC, CA | $3,036,135 | ZDA1 |
| 2019 | Clinical Evaluation of C4X3256, a Non-Opioid, Highly-Selective Orexin-1 Receptor Antagonist for the Treatment of Opioid Use Disorder1UG3DA050308-01 · under RFA-DA-19-002 | HEIDBREDER, CHRISTIAN ARTHUR | INDIVIOR, INC., VA | $3,016,228 | ZDA1 |
| 2019 | Development of a Potent and Highly Selective NaV1.7 Inhibitor for the Treatment of Acute Pain with the Goal of Reducing Opioid Use and Preventing Opioid Use Disorders1UG3DA049599-01 · under RFA-DA-19-002 | HUNTER, JOHN CURETONODINK, DEBRA | SITEONE THERAPEUTICS, INC., CA | $2,937,963 | ZDA1 |
| 2019 | The long-term reduction of pain and opioid usage following mastectomy and tissue expander/implant surgery with a single administration of brivoligide, a non-opioid, disease-modifying drug candidate1UG3DA048375-01 · under RFA-DA-19-002 | MAMET, JULIENMANNING, DONALD C | ADYNXX, INC., CA | $2,858,544 | ZDA1 |
| 2019 | Development of a 3-month implantable depot pellet of Naltrexone for the treatment of Opioid Use Disorder.1UG3DA047925-01 · under RFA-DA-19-002 | BRAR, BALBIR | BIOCORRX, INC., CA | $2,842,430 | ZDA1 |
| 2019 | Advancing KNX100 for the treatment of opioid withdrawal: preclinical efficacy and toxicology, and a phase 1 clinical program.1UG3DA048743-01 · under RFA-DA-19-002 | ALSOP, HUGH WILLIAMBOWEN, MICHAEL THOMASMCGREGOR, IAIN STEWART | KINOXIS THERAPEUTICS PTY LTD | $2,798,940 | ZDA1 |
| 2019 | Methocinnamox (MCAM): A novel õ-opioid receptor antagonist for opioid use disorders1UG3DA048387-01A1 · under RFA-DA-19-002 | FRANCE, CHARLES P | UNIVERSITY OF TEXAS HLTH SCIENCE CENTER, TX | $2,750,111 | ZDA1 |
| 2019 | 1-Year Sustained Release Naltrexone Implant for the prevention of relapse to opioid dependence1UG3DA050306-01 · under RFA-DA-19-002 | MARTIN, FRANCIS JOSEPH | DELPOR, INC., CA | $2,572,678 | ZDA1 |
| 2019 | A novel therapeutic to ameliorate chronic pain and reduce opiate use1UG3DA047680-01 · under RFA-DA-19-002 | TABAKOFF, BORIS | LOHOCLA RESEARCH CORPORATION, CO | $2,382,426 | ZDA1 |
| 2019 | Use of a GLP-1 Agonist to Treat Opioid Use Disorder in Rats and Man1UG3DA050325-01 · under RFA-DA-19-002 | BUNCE, SCOTT CGRIGSON, PATRICIA SUE | PENNSYLVANIA STATE UNIV HERSHEY MED CTR, PA | $2,367,195 | ZDA1 |
| 2019 | Targeting the Ghrelin System for Novel Opioid Use Disorder Therapeutics1UG3DA050317-01 · under RFA-DA-19-002 | CUNNINGHAM, KATHRYN A. | UNIVERSITY OF TEXAS MED BR GALVESTON, TX | $2,230,347 | ZDA1 |
| 2019 | Preclinical and clinical evaluation of the NMDA modulator NYX-783 for OUD1UG3DA050322-01 · under RFA-DA-19-002 | DILEONE, RALPH JMALISON, ROBERT TSINHA, RAJITATAYLOR, JANE R | YALE UNIVERSITY, CT | $2,182,107 | ZDA1 |
| 2019 | Development of an implantable closed-loop system for delivery of naloxone for the prevention of opioid-related overdose deaths1UG3DA050303-01 · under RFA-DA-19-002 | GEREAU, ROBERT WROGERS, JOHN | WASHINGTON UNIVERSITY, MO | $2,096,911 | ZDA1 |
| 2019 | Opioid use disorders: UF Pharmacy medications discovery and development1UG3DA048353-01 · under RFA-DA-19-002 | MCCURDY, CHRISTOPHER RMCMAHON, LANCE R. | UNIVERSITY OF FLORIDA, FL | $2,023,489 | ZDA1 |
| 2019 | Novel LAAM formulations to treat Opioid Use Disorder (UG3 DA048768-01A1)1UG3DA048768-01A1 · under RFA-DA-19-002 | HALQUIST, MATTHEW SEANMOELLER, FREDERICK GERARDO'KEEFFE, CHARLESXU, QINGGUO | VIRGINIA COMMONWEALTH UNIVERSITY, VA | $1,614,668 | ZDA1 |
| 2019 | Vaccines for fentanyl and its derivatives: A strategy to reduce illicit use and overdose1UG3DA048386-01 · under RFA-DA-19-002 | PRAVETONI, MARCO | UNIVERSITY OF MINNESOTA, MN | $1,562,143 | ZDA1 |
| 2019 | Novel nanovaccines against opioid use disorders1UG3DA048775-01 · under RFA-DA-19-002 | PRAVETONI, MARCOZHANG, CHENMING M | VIRGINIA POLYTECHNIC INST AND ST UNIV, VA | $1,537,430 | ZDA1 |
| 2019 | Development of Next-generation Pharmacotherapy for Opioid Use Disorders1UG3DA048371-01 · under RFA-DA-19-002 | ZAVERI, NURULAIN T | ASTRAEA THERAPEUTICS, LLC, CA | $1,458,094 | ZDA1 |
| 2019 | Evaluating Suvorexant for Sleep Disturbance in Opioid Use Disorder1UG3DA048734-01 · under RFA-DA-19-002 | DUNN, KELLY EHUHN, ANDREW S | JOHNS HOPKINS UNIVERSITY, MD | $1,139,075 | ZDA1 |
| 2019 | Mu Opioid Receptor Modulator Development to Treat Opioid Use Disorder1UG3DA050311-01 · under RFA-DA-19-002 | ZHANG, YAN | VIRGINIA COMMONWEALTH UNIVERSITY, VA | $996,755 | ZDA1 |
| 2019 | MOR/DOR Heterodimer Antagonists: A Novel Treatment for Opioid Dependence1UG3DA047717-01 · under RFA-DA-19-002 | MORGAN, MICHAEL M | WASHINGTON STATE UNIVERSITY, WA | $922,540 | ZDA1 |
| 2019 | Injectable naltrexone 2-month depot formulations1UG3DA048774-01 · under RFA-DA-19-002 | PARK, KINAM | PURDUE UNIVERSITY, IN | $712,935 | ZDA1 |
| 2018 | Phase 1a/1b Clinical Trials of Multivalent Opioid Vaccine Components1UG3DA047711-01 · under RFA-DA-19-002 | COMER, SANDRA DPRAVETONI, MARCO | NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC, NY | $4,121,081 | ZDA1 |
| 2018 | A Phase I/IIa Clinical Trial Testing the Safety and Immunogenicity of a Heroin Vaccine and its Efficacy Against Morphine Challenge.1UG3DA048351-01 · under RFA-DA-19-002 | MATYAS, GARY R. | HENRY M. JACKSON FDN FOR THE ADV MIL/MED, MD | $3,690,224 | ZDA1 |
| 2018 | Evaluation of safety and pharmacokinetics of naltrexone implant1UG3DA047720-01 · under RFA-DA-19-002 | BISAGA, ADAMNUNES, EDWARD V. | NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC, NY | $3,010,138 | ZDA1 |
| 2018 | Nalmefene Implant for the Long-Term Treatment of Opioid Use Disorder1UG3DA047707-01 · under RFA-DA-19-002 | BEEBE DEVARNEY, KATHERINE | TITAN PHARMACEUTICALS, INC., CA | $2,666,592 | ZDA1 |
| 2018 | An ultra-long-acting oral treatment for opioid use disorder1UG3DA047709-01 · under RFA-DA-19-002 | BELLINGER, ANDREW MARTIN | LYNDRA THERAPEUTICS, INC., MA | $2,543,976 | ZDA1 |
| 2018 | PF614 MPAR Abuse Deterrent opioid prodrug with overdose protection: Pre-Clinical Development and Phase 1 Clinical Trial1UG3DA047682-01 · under RFA-DA-19-002 | KIRKPATRICK, LYNN | ENSYSCE BIOSCIENCES, INC., CA | $2,123,989 | ZDA1 |
| 2018 | Development of novel therapeutics for opioid dependence1UG3DA048385-01 · under RFA-DA-19-002 | KAMENECKA, THEODORE MKENNY, PAUL J. | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $2,007,235 | ZDA1 |
| 2018 | Biased Mu-Opioid Receptor Analgesics to Prevent Overdose and Opioid Use Disorders1UG3DA047700-01 · under RFA-DA-19-002 | BARRETT, JAMES E.KUO, LAWRENCE C | MEBIAS DISCOVERY, INC., PA | $893,396 | ZDA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.